MedTrace Logo

National CounterACT Initiative

NCT03597438 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 236

Last updated 2024-02-23

No results posted yet for this study

Summary

The purpose of the study is to determine in vitro effects on mitochondrial function of selected chemical agents in human cells, and assess the capability of a cell-permeable succinate prodrug to attenuate toxic effects The project aims at repurposing this recent pharmaceutical discovery, currently being developed for treatment of toxic exposure, for an expanded indication to treat chemically induced mitochondrial toxicity.

Conditions

  • Mitochondrial Alteration

Sponsors & Collaborators

Principal Investigators

  • Todd J Kilbaugh, MD · Children's Hospital of Philadelphia

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-07
Primary Completion
2023-04-18
Completion
2024-02-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03597438 on ClinicalTrials.gov